Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Senesco Presents Pre-Clinical Multiple Myeloma Data At The 12th Annual Meeting Of The American Society Of Gene Therapy
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco"s multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, from Wednesday, May 27th through to Saturday, May 30th, 2009. Mr. Dondero will be presenting in the afternoon session on Thursday, May 28th.
generic viagra online
Massachusetts Hospital Sues State Over Cost Of Universal Care
"A hospital that serves thousands of indigent Massachusetts residents sued the state on Wednesday, charging that its costly universal health care law is forcing the hospital to cover too much of the expense of caring for the poor," according to the New York Times.
News of the day
More Vigilant Monitoring For Seizures Among ICU Patients Encouraged
Two new studies published by neurologists at Columbia University Medical Center and NewYork-Presbyterian Hospital demonstrate a need for more vigilant monitoring for seizure activity among intensive care patients who may be experiencing subtle seizures that are typically unrecognized. These subtle seizures may be affecting patients" prognoses and causing long-term brain damage, death and severe disability.
Medical Devices

BIO Comments On Medicare Drug Discount Agreement Announced By PhRMA, The White House And Senate Finance Committee

The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding the agreement reached among the Obama administration, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Senate Finance Committee to help close the coverage gap in the Medicare prescription drug program: "We look forward to reviewing in greater detail the agreement struck among President Obama, PhRMA and the Senate Finance Committee. "We will examine the deal through the lens of measuring its impact on the ability of biotechnology researchers to continue to develop and produce breakthrough medicines and therapies that extend and improve the quality of life - and provide renewed hope - for patients suffering from debilitating diseases such as cancer, Parkinson"s, Multiple Sclerosis and a host of rare diseases. "We share the goal of ensuring that all Americans have access to high quality health care. We look forward to continuing our participation in the process of reforming our nation"s health care system to increase access and reduce costs while promoting the continued development of new therapies and cures." BIO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009